Free Trial

Genus (LON:GNS) Issues Quarterly Earnings Results

Genus logo with Medical background
Remove Ads

Genus (LON:GNS - Get Free Report) posted its earnings results on Thursday. The company reported GBX 39.80 ($0.51) EPS for the quarter, Digital Look Earnings reports. Genus had a return on equity of 1.41% and a net margin of 1.18%.

Genus Stock Performance

LON:GNS traded up GBX 2.66 ($0.03) during trading hours on Monday, reaching GBX 1,828.82 ($23.24). 268,720 shares of the company's stock were exchanged, compared to its average volume of 136,445. Genus has a 1-year low of GBX 1,424 ($18.10) and a 1-year high of GBX 2,155 ($27.39). The company has a quick ratio of 1.08, a current ratio of 1.80 and a debt-to-equity ratio of 53.12. The firm has a market capitalization of £1.20 billion, a price-to-earnings ratio of 151.59, a P/E/G ratio of 2.87 and a beta of 0.37. The company has a 50-day moving average of GBX 1,715.47 and a 200 day moving average of GBX 1,799.09.

Wall Street Analysts Forecast Growth

Separately, Shore Capital reaffirmed a "buy" rating on shares of Genus in a research report on Wednesday, December 11th.

Read Our Latest Report on Genus

Insider Buying and Selling at Genus

In other news, insider Jorgen Kokke sold 19,967 shares of Genus stock in a transaction dated Friday, February 28th. The shares were sold at an average price of GBX 1,731 ($22.00), for a total value of £345,628.77 ($439,228.33). 0.75% of the stock is currently owned by company insiders.

About Genus

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

Read More

Should You Invest $1,000 in Genus Right Now?

Before you consider Genus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.

While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Time to Buy SoFi? Fintech’s Next Big Move
3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?
Why Palantir’s Future Just Got a Massive Boost

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads